Sortilin and homocysteine as potential biomarkers for coronary artery diseases

Abstract

Purpose: The aim of this study was to assess the relationship of coronary artery disease (CAD) with levels of homocysteine and sortilin in Egyptian patients. Background: CAD is a primary contributor to cardiac disease and a prominent cause of death globally. Patients and Methods: We enrolled 45 patients with CAD evaluated by coronary CT angiography and 42 control subjects without CAD. Plasma-homocysteine and-sortilin levels were measured with a commercial ELISA kit. Results: Elevated levels of homocysteine and sortilin were observed in the CAD patients compared to controls (13.75±1.40 vs 7.73±2.06 μmol/L, P=0 and 160.91±32.17 vs 143.02 ±32.30 ng/dL, P=0.02, respectively). Significantly higher total cholesterol, low density– lipoprotein cholesterol and triglycerides (P<0.05) and lower high density–lipoprotein cholesterol (P<0.05) were seen among patients with CAD than the control group. Sortilin levels were positively associated with homocysteine levels (r=0.32, P=0.006), total cholesterol (r=0.61, P=0), low density–lipoprotein cholesterol (r=0.37, P=0.001), triglycerides (r=0.91, P=0), troponin I (r=0.82, P=0), Gensini score (r=0.93, P=0) and high-sensitivity CRP (r=0.87, P=0) in all subjects. Homocysteine has a significantly negative association with high density–lipoprotein cholesterol (r=−0.42, P=0). Conclusion: Elevated homocysteine and sortilin levels are crucial risk factors of CAD in Egyptian patients.